相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Pathogenic Variants in Complement Genes and Risk of Atypical Hemolytic Uremic Syndrome Relapse after Eculizumab Discontinuation
Fadi Fakhouri et al.
CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2017)
Improved renal recovery in patients with atypical hemolytic uremic syndrome following rapid initiation of eculizumab treatment
Johan Vande Walle et al.
JOURNAL OF NEPHROLOGY (2017)
Can eculizumab be discontinued in aHUS? Case report and review of the literature
Tuncay Sahutoglu et al.
MEDICINE (2016)
Discontinuation of Eculizumab Treatment in Atypical Hemolytic Uremic Syndrome: An Update
Gianluigi Ardissino et al.
AMERICAN JOURNAL OF KIDNEY DISEASES (2015)
Update on paroxysmal nocturnal haemoglobinuria: on the long way to understand the principles of the disease
Joerg Schubert et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2015)
Therapeutic drug monitoring of eculizumab: Rationale for an individualized dosing schedule
Philippe Gatault et al.
MABS (2015)
Opportunity Cost of Funding Drugs for Rare Diseases: The Cost-Effectiveness of Eculizumab in Paroxysmal Nocturnal Hemoglobinuria
Doug Coyle et al.
MEDICAL DECISION MAKING (2014)
Genetic Variants in C5 and Poor Response to Eculizumab
Jun-ichi Nishimura et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Targeting complement system to treat myasthenia gravis
Ruksana Huda et al.
REVIEWS IN THE NEUROSCIENCES (2014)
Complement in paroxysmal nocturnal hemoglobinuria: exploiting our current knowledge to improve the treatment landscape
Dimitrios C. Mastellos et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Combined Complement Gene Mutations in Atypical Hemolytic Uremic Syndrome Influence Clinical Phenotype
Elena Bresin et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2013)
A randomized, double-blind, placebo-controlled phase II study of eculizumab in patients with refractory generalized myasthenia gravis
James F. Howard et al.
MUSCLE & NERVE (2013)
Terminal Complement Inhibitor Eculizumab in Atypical Hemolytic-Uremic Syndrome
C. M. Legendre et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival
Richard J. Kelly et al.
BLOOD (2011)
Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria
Anita Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab
Antonio M. Risitano et al.
BLOOD (2009)
Autoimmune myasthenia gravis: emerging clinical and biological heterogeneity
Matthew N. Meriggioli et al.
LANCET NEUROLOGY (2009)
What not to learn from a meta-analysis
Marina Noris et al.
NATURE REVIEWS NEPHROLOGY (2009)
Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria
Joerg Schubert et al.
BRITISH JOURNAL OF HAEMATOLOGY (2008)
Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria
Russell P. Rother et al.
NATURE BIOTECHNOLOGY (2007)
Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria
Anita Hill et al.
BRITISH JOURNAL OF HAEMATOLOGY (2007)
The pathophysiology of paroxysmal nocturnal hemoglobinuria
Charles J. Parker
EXPERIMENTAL HEMATOLOGY (2007)
The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria
Peter Hillmen et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
The development of atypical haemolytic-uraemic syndrome is influenced by susceptibility factors in factor H and membrane cofactor protein: evidence from two independent cohorts
V Fremeaux-Bacchi et al.
JOURNAL OF MEDICAL GENETICS (2005)
The clinical sequelae of intravascular hemolysis and extracellular plasma hemoglobin - A novel mechanism of human disease
RP Rother et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Inhibition of complement neutrophil, and platelet activation by an anti-factor D monoclonal antibody in simulated cardiopulmonary bypass circuits
M Fung et al.
JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY (2001)
分享论文
